about
Differential effects of the catechol-O-methyltransferase Val158Met genotype on the cognitive function of schizophrenia patients and healthy Japanese individualsComparison of ankle-brachial pressure index and pulse wave velocity as markers of cognitive function in a community-dwelling population.Clock drawing performance in a community-dwelling population: Normative data for Japanese subjects.The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.Dietary patterns are associated with obesity in Japanese patients with schizophrenia.The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary studyGenomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p.Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder.Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response.Neuroleptic malignant syndrome induced by lamotrigine.Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis.Body mass index and quality of life among outpatients with schizophrenia in JapanHyperprolactinemia during antipsychotics treatment increases the level of coagulation markers.Cognitive function among hemodialysis patients in Japan.Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia.Hearing impairment and cognitive function among a community-dwelling population in Japan.Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsyDietary patterns and schizophrenia: a comparison with healthy controls.ABO Blood Type and Personality Traits in Healthy Japanese Subjects.Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.Effect of age and disease on bone mass in Japanese patients with schizophrenia.Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypesEffects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypesEffects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypesDifferent effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in JapanNo association between CYP2D6 polymorphisms and personality trait in JapaneseAn attempt to construct a 7-item short version of the temperament and character inventory to predict the treatment response of patients with depression; a validation studySerotonin syndrome induced by the readministration of escitalopram after a short-term interruption in an elderly woman with depression: a case report.Effect of depressive symptoms on the length of hospital stay among patients hospitalized for acute stroke in Japan.High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide SurveyThe low level of understanding of depression among patients treated with antidepressants: a survey of 424 outpatients in JapanThe association between the subjective memory complaints scale and depressive state and cognitive impairment: a factor analysis.High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia: a nationwide survey.Body composition in patients with schizophrenia: Comparison with healthy controls.No association between dietary patterns and depressive symptoms among a community-dwelling population in Japan.Attitudes toward metabolic adverse events among patients with schizophrenia in Japan.Relationship between the lesion location of acute ischemic stroke and early depressive symptoms in Japanese patients.
P50
Q31144520-9257A757-55AE-4E93-A4F9-32E9CBC9307CQ33600269-D25A7D94-CA0F-46B4-8228-A7602E65B158Q33627869-72F0225E-198F-44FF-B5A7-07895897F0D3Q33654737-9319CF92-C88C-4234-96DD-678708634492Q33865512-3B454EA4-B158-4157-87F4-59CA6681EEA7Q34110039-47D49F64-79C2-478B-B0BA-6B127879C2D5Q34137538-19324694-0946-45B7-9156-6C10A3FBE2B8Q34238795-3AD242A6-8CF1-4EFF-A381-1B6B12AFC7F6Q34333832-2FACFD81-5BF4-4304-A5D0-6FA512F50454Q34352024-E43F1E17-B774-41B5-BB76-80E3D629B736Q34456179-BB50AF53-F885-4AEB-BCDC-887DD5640CE3Q34660592-A354A564-BB57-4BCB-8DB2-D8D7A09E668AQ35142660-2F86F332-02A3-47BB-8916-881CAF32A215Q35209722-F889EF82-3DBC-4C75-9A08-C82A8E83F82EQ35230391-47B35D26-F885-42AA-9F5D-104C7F3D3563Q35338440-6803A94F-12B1-4355-A1D6-E4D50827C731Q35427844-7DF4D78D-1D5A-4E9F-AD53-9916771D5192Q35542335-2DE3E4CF-36DC-4260-B4EE-A1D501762616Q35610882-14F7B920-5C47-44C9-AE31-9ADE540BA4F2Q35814413-EE4D60A1-0EE3-4ABD-B045-3DB78C9CE29DQ35818254-5738FD8D-77FF-4518-BBD7-F059A869B7D5Q35826075-9C7911B8-C824-4158-A285-02348A8982D0Q35826139-01D2166B-4EEB-4B68-BD87-2F293D3BC253Q35826832-4DDD5450-A8FF-46C9-AAD8-2A361C4794A6Q35827117-4159E04B-4089-44D2-A8CE-CD889C9810DEQ35827444-4DA7B28F-6BA5-4253-AC71-5E0A51E17837Q35827487-1AE24A0D-4E7A-48C2-A608-11D18D91B7BEQ35850831-BBDF45CD-AD73-4791-9273-3623DA8AB107Q36024499-6886D932-5E64-4348-9FA1-E7904125DA7AQ36103325-D62BB702-B42F-481B-9CBB-4C15C30A49ECQ36140539-F797F9F7-11DF-4B5A-86F4-11E97C8DAF88Q36142290-DF48C29E-AAC2-45D6-978F-0CD25AD5B6B3Q36195246-E56CBAE6-CB26-48D6-B41C-BC3BE3759F98Q36240660-E64837B7-A144-414D-ACC2-B4118DBFFB49Q36332447-BB2F79F5-F21C-42ED-B8B2-3785B4829E82Q36374026-56900034-4805-4B54-8A12-C2B7C16A6E57Q36388181-B130C3E3-C8E1-4DAD-9147-F1C6D499D615Q36493987-42490AD5-0141-4074-9A76-4A5994FCEFB4Q36631551-759D4372-80FC-4A32-BDC5-7FB1B5E99B77Q36758351-C5E9DEBC-8589-4C1A-88C3-7CC3C2200450
P50
name
Norio Yasui-Furukori
@ast
Norio Yasui-Furukori
@en
Norio Yasui-Furukori
@nl
type
label
Norio Yasui-Furukori
@ast
Norio Yasui-Furukori
@en
Norio Yasui-Furukori
@nl
prefLabel
Norio Yasui-Furukori
@ast
Norio Yasui-Furukori
@en
Norio Yasui-Furukori
@nl